Reformulating cyclosporine A (CsA): More than just a life cycle management strategy

Journal of Controlled Release

Volumn 225, Issue , 2016, Pages 269-282

  Guada, Melissa ^a,b   Beloqui, Ana ^c   Kumar, M N V Ravi ^d   Preát, Véronique ^c   Dios Vieítez, Maria Del Carmen ^a,b   Blanco Prieto, Maria J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Recinto de Complejo Hospitalario de Navarra   (Spain)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cyclosporine A; Drug delivery system; Immunosuppressant; Microparticle; Nanoparticle

Indexed keywords

BIOCHEMISTRY; GRAFTS; LIFE CYCLE; NANOPARTICLES;

AUTOIMMUNE DISORDER; CYCLOSPORINE A; DRUG DELIVERY SYSTEM; IMMUNOSUPPRESSANT; IMMUNOSUPPRESSIVE AGENT; LIFE-CYCLE MANAGEMENT; MICRO PARTICLES; REVERSIBLE INHIBITIONS;

DRUG PRODUCTS;

CREATININE; CYCLOSPORIN A; NANOCARRIER; UREA; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ASTHMA; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CREATININE BLOOD LEVEL; DRUG DELIVERY SYSTEM; ELECTROLYTE DISTURBANCE; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HIRSUTISM; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MYASTHENIA GRAVIS; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UREA BLOOD LEVEL; ANIMAL; CHEMISTRY; DRUG FORMULATION;

ANIMALS; CYCLOSPORINE; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84959431466     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.01.056     Document Type: Review

References (101)

1. S.A. Survase, L.D. Kagliwal, U.S. Annapure, and R.S. Singhal Cyclosporin A-a review on fermentative production, downstream processing and pharmacological applications Biotechnol. Adv. 29 2011 418 435
2. A. Pawarode, P.K. Wallace, L.A. Ford, M. Barcos, and M.R. Baer Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia Leuk. Lymphoma 51 2010 338 341
3. D. Lulic, J. Burns, E.C. Bae, H. van Loveren, and C.V. Borlongan A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury Neurosurgery 68 2011 1172 1185 (discussion 1185-1186)
4. M.M. Osman, D. Lulic, L. Glover, C.E. Stahl, T. Lau, H. van Loveren, and C.V. Borlongan Cyclosporine-A as a neuroprotective agent against stroke: Its translation from laboratory research to clinical application Neuropeptides 45 2011 359 368
5. S. Hamdy, A. Haddadi, A. Shayeganpour, A. Alshamsan, H.M. Aliabadi, and A. Lavasanifar The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: In vitro and in vivo studies AAPS J. 13 2011 159 168
6. Y. Lei, J. Qi, S. Nie, F. Hu, W. Pan, Y. Lu, and W. Wu Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: Stability and bioavailability study J. Biomed. Nanotechnol. 8 2012 515 521
7. L. Zhang, Z. Zhao, X. Wei, and J. Liu Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles Int. J. Nanomedicine 8 2013 601 610
8. W. Dai, Y. Guo, H. Zhang, X. Wang, and Q. Zhang Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A Int. J. Pharm. 478 2015 718 725
9. P.R. Beauchesne, N.S. Chung, and K.M. Wasan Cyclosporine A: A review of current oral and intravenous delivery systems Drug Dev. Ind. Pharm. 33 2007 211 220
10. N. El Tayar, A.E. Mark, P. Vallat, R.M. Brunne, B. Testa, and W.F. van Gunsteren Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: Evidence from partition coefficients and molecular dynamics simulations J. Med. Chem. 36 1993 3757 3764
11. R.M. Wenger, T.G. Payne, and M.H. Schreier Cyclosporine: Chemistry, structure-activity relationships and mode of action Anonymous Metabolic Control in Diabetes Mellitus Beta Adrenoceptor Blocking Drugs NMR Analysis of Cancer Cells Immunoassay in the Clinical Laboratory Cyclosporine 1986 Springer 157 191
12. S. Matsuda, and S. Koyasu Mechanisms of action of cyclosporine Immunopharmacology 47 2000 119 125
13. T. Archer, D. Boothe, V. Langston, C. Fellman, K. Lunsford, and A. Mackin Oral cyclosporine treatment in dogs: A review of the literature J. Vet. Intern. Med. 28 2014 1 20
14. D. Hausenloy, E. Boston-Griffiths, and D. Yellon Cyclosporin A and cardioprotection: From investigative tool to therapeutic agent Br. J. Pharmacol. 165 2012 1235 1245
15. A. Lindholm Factors influencing the pharmacokinetics of cyclosporine in man Ther. Drug Monit. 13 1991 465 477
16. D. Freeman Pharmacology and pharmacokinetics of cyclosporine Clin. Biochem. 24 1991 9 14
17. U. Christians, and K. Sewing Cyclosporin metabolism in transplant patients Pharmacol. Ther. 57 1993 291 345
18. European Multicentre Trial Group Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial Lancet 322 1983 986 989
19. J.R. Azzi, M.H. Sayegh, and S.G. Mallat Calcineurin inhibitors: 40 years later, can't live without J. Immunol. 191 2013 5785 5791
20. A. Weber, F. Fein, S. Koch, A. Dupont-Gossart, G. Mantion, B. Heyd, and F. Carbonnel Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral) Inflamm. Bowel Dis. 12 2006 1131 1135
21. A. Kornbluth Cyclosporine versus infliximab for the treatment of severe ulcerative colitis Gastroenterol. Hepatol. 7 2011 677 679
22. X. Zhao, K. Zhou, L. Jing, L. Zhang, G. Peng, Y. Li, L. Ye, J. Li, H. Fan, and Y. Li Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: Experience in a Chinese single institution Leuk. Res. 37 2013 547 551
23. J.L. Italia, V. Bhardwaj, and M.N.V. Ravi Kumar Disease, destination, dose and delivery aspects of ciclosporin: The state of the art Drug Discov. Today 11 2006 846 854
24. P.E. Wallemacq Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin. Chem. Lab. Med. 42 2004 1204 1211
25. G. Feutren The optimal use of cyclosporin A in autoimmune diseases J. Autoimmun. 5 1992 183 195
26. N. Issa, A. Kukla, and H.N. Ibrahim Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence Am. J. Nephrol. 37 2013 602 612
27. C.H. Lee, and G. Kim Electrolyte and Acid-Base disturbances induced by clacineurin inhibitors 5 2007 Electrolyte Blood Press 126 130
28. M. Naesens, D.R. Kuypers, and M. Sarwal Calcineurin inhibitor nephrotoxicity Clin. J. Am. Soc. Nephrol. 4 2009 481 508
29. W.M. Bennet, and D.J. Norman Action and toxicity of cyclosporine Annu. Rev. Med. 37 1986 215 224
30. A. Lindholm, S. Henricsson, M. Lind, and R. Dahlqvist Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing Eur. J. Clin. Pharmacol. 34 1988 461 464
31. Y.Y. Chiu, K. Higaki, B.L. Neudeck, J.L. Barnett, L.S. Welage, and G.L. Amidon Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in caco-2 cells Pharm. Res. 20 2003 749 756
32. T. Andrysek Impact of physical properties of formulations on bioavailability of active substance: Current and novel drugs with cyclosporine Mol. Immunol. 39 2003 1061 1065
33. J. Schiff, E. Cole, and M. Cantarovich Therapeutic monitoring of calcineurin inhibitors for the nephrologist Clin. J. Am. Soc. Nephrol. 2 2007 374 384
34. D.J. Taber, G.M. Baillie, E.E. Ashcraft, J. Rogers, A. Lin, F. Afzal, P. Baliga, P.R. Rajagopalan, and K.D. Chavin Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 80 2005 1633 1635
35. B. Steve Campbell, E. Elmér, M. Bronnegard, TBI Pharmaceuticals-The long odyssey of cyclosporine is almost over, http://www.internationalbrain.org/tbi-pharmaceuticals-the-long-odyssey-of-cyclosporine/(last access: 10/22/2015).
36. K.H.J. Ehinger, M.J. Hansson, F. Sjövall, and E. Elmér Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in cremophor® EL Clin. Drug Invest. 33 2013 25 34
37. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
38. P. Barany, P. Stenvinkel, A. Ottosson-Seeberger, A. Alvestrand, J. Morrow, J.J. Roberts 2nd, and A.K. Salahudeen Effect of 6 weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers Nephrol. Dial. Transplant. 16 2001 580 584
39. F. Lallemand, O. Felt-Baeyens, K. Besseghir, F. Behar-Cohen, and R. Gurny Cyclosporine A delivery to the eye: A pharmaceutical challenge Eur. J. Pharm. Biopharm. 56 2003 307 318
40. J. Shen, Y. Deng, X. Jin, Q. Ping, Z. Su, and L. Li Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution Int. J. Pharm. 402 2010 248 253
41. E. Basaran, M. Demirel, B. Sirmagül, and Y. Yazan Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery J. Microencapsul. 27 2010 37 47
42. G. Sandri, M.C. Bonferoni, E.H. Gokce, F. Ferrari, S. Rossi, M. Patrini, and C. Caramella Chitosan-associated SLN: In vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems J. Microencapsul. 27 2010 735 746
43. L. Battaglia, I. D'Addino, E. Peira, M. Trotta, and M. Gallarate Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine J. Drug Delivery Sci. Technol. 22 2012 125 130
44. E. Wolska, and M. Sznitowska Technology of stable, prolonged-release eye-drops containing cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM) Int. J. Pharm. 441 2013 449 457
45. M. Guada, V. Sebastián, S. Irusta, E. Feijoó, M.C. Dios-Vieítez, and M.J. Blanco-Prieto Lipid nanoparticles for cyclosporine A administration: Development, characterization and in vitro evaluation of their immunosuppression activity Int. J. Nanomedicine 10 2015 6541 6553
46. M. Guada, B. Lasa-Saracíbar, H. Lana, M.C. Dios-Vieítez, and M.J. Blanco-Prieto Lipid nanoparticles enhance the absorption of Cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies Int. J. Pharm. 500 2016 154 161
47. S. Jain, S. Kambam, K. Thanki, and A.K. Jain Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): Implication of functional Excipient Based Co-encapsulation strategy on oral bioavailability and nephrotoxicity RSC Adv. 2015 49633 49642
48. X. Zhang, Y. Yi, J. Qi, Y. Lu, Z. Tian, Y. Xie, H. Yuan, and W. Wu Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: Near zero-order release and pharmacokinetics in dogs Int. J. Pharm. 452 2013 233 240
49. A. Avramoff, W. Khan, A. Ezra, A. Elgart, A. Hoffman, and A.J. Domb Cyclosporin pro-dispersion liposphere formulation J. Control. Release 160 2012 401 406
50. A. Avramoff, A. Laor, R. Kitzes-Cohen, D. Farin, and A.J. Domb Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations Int. J. Clin. Pharmacol. Ther. 45 2007 126 132
51. P. Guan, Y. Lu, J. Qi, M. Niu, R. Lian, F. Hu, and W. Wu Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt Int. J. Nanomedicine 6 2011 965 974
52. S.Y. Karavana, E.H. Gökçe, S. Rençber, S. Özbal, Ç. Pekçetin, P. Güneri, and G. Ertan A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: In vivo/in vitro examinations Int. J. Nanomedicine 7 2012 5693 5704
53. Q. Yin, Z. Pei, H. Wang, and Y. Zhao Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue-derived stem cell transplantation in a swine myocardial infarction model Int. J. Nanomedicine 9 2014 17 26
54. L. Gan, J. Wang, M. Jiang, H. Bartlett, D. Ouyang, F. Eperjesi, J. Liu, and Y. Gan Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers Drug Discov. Today 18 2013 290 297
55. E.B. Souto, S. Doktorovova, E. Gonzalez-Mira, M.A. Egea, and M.L. Garcia Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs Curr. Eye Res. 35 2010 537 552
56. R.H. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
57. M. Alonso-Sande, A. des Rieux, V. Fievez, B. Sarmento, A. Delgado, C. Evora, C. Remunãn-López, V. Preát, and M.J. Alonso Development of PLGA-mannosamine nanoparticles as oral protein carriers Biomacromolecules 14 2013 4046 4052
58. A.M. De Campos, A. Sánchez, and M.J. Alonso Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A Int. J. Pharm. 224 2001 159 168
59. A. Beloqui, M.A. Solinís, A. Rodríguez-Gascón, A.J. Almeida, and V. Preát Nanostructured lipid carriers: Promising drug delivery systems for future clinics Nanomedicine 12 2016 143 161
60. P.B. Memvanga, R. Coco, and V. Preát An oral malaria therapy: Curcumin-loaded lipid-based drug delivery systems combined with β-arteether J. Control. Release 172 2013 904 913
61. L. Sercombe, T. Veerati, F. Moheimani, S.Y. Wu, A.K. Sood, and S. Hua Advances and challenges of liposome assisted drug delivery Front. Pharmacol. 6 2015 286
62. W. Wu, Y. Lu, and J. Qi Oral delivery of liposomes Ther. Deliv. 6 2015 1239 1241
63. S. Hu, M. Niu, F. Hu, Y. Lu, J. Qi, Z. Yin, and W. Wu Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media Int. J. Pharm. 441 2013 693 700
64. Z. Rahman, A.S. Zidan, M.J. Habib, and M.A. Khan Understanding the quality of protein loaded PLGA nanoparticles variability by plackett-Burman design Int. J. Pharm. 389 2010 186 194
65. K. Hermans, W. Weyenberg, and A. Ludwig The effect of HPβCD on cyclosporine A in-vitro release from PLGA nanoparticles J. Control. Release 148 2010 e40 e41
66. G. Takebe, T. Takagi, M. Suzuki, and M. Hiramatsu Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser Int. J. Pharm. 414 2011 244 250
67. R.A. Bader, A.L. Silvers, and N. Zhang Polysialic acid-based micelles for encapsulation of hydrophobic drugs Biomacromolecules 12 2011 314 320
68. K. Jelonek, J. Kasperczyk, S. Li, P. Dobrzynski, and B. Jarzabek Controlled poly (l-lactide-co-trimethylene carbonate) delivery system of cyclosporine A and rapamycine-the effect of copolymer chain microstructure on drug release rate Int. J. Pharm. 414 2011 203 209
69. L. Tang, J. Azzi, M. Kwon, M. Mounayar, R. Tong, Q. Yin, R. Moore, N. Skartsis, T.M. Fan, and R. Abdi Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A J. Transplant. 2012 2012 896141
70. K. Hermans, D. Van den Plas, A. Everaert, W. Weyenberg, and A. Ludwig Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles Eur. J. Pharm. Biopharm. 82 2012 27 35
71. D.R. Wilson, N. Zhang, A.L. Silvers, M.B. Forstner, and R.A. Bader Synthesis and evaluation of cyclosporine A-loaded polysialic acid-polycaprolactone micelles for rheumatoid arthritis Eur. J. Pharm. Sci. 51 2014 146 156
72. Z. Rahman, A.S. Zidan, and M.A. Khan Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods AAPS J. 12 2010 158 170
73. K. Keohane, D. Brennan, P. Galvin, and B.T. Griffin Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles Int. J. Pharm. 467 2014 60 69
74. K. Mondon, M. Zeisser-Labouèbe, R. Gurny, and M. Möller Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: A suitability study Eur. J. Pharm. Biopharm. 77 2011 56 65
75. Y. Cao, M. Roursgaard, A. Kermanizadeh, S. Loft, and P. Moller Synergistic effects of zinc oxide nanoparticles and fatty acids on toxicity to caco-2 cells Int. J. Toxicol. 34 2015 67 76
76. D.D. Ankola, A. Battisti, R. Solaro, and M.N. Kumar Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A J. R. Soc. Interface 7 Suppl. 4 2010 S475 S481
77. D. Ankola, R. Wadsworth, and M. Ravi Kumar Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral cmax sparing the kidney from damage J. Biomed. Nanotechnol. 7 2011 300 307
78. V. Venkatpurwar, S. Rhodes, K. Oien, M. Elliott, C. Tekwe, H. Jørgensen, and M.R. Kumar Drug-not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano-and micro-particles: Size does not matter Toxicology 330 2015 9 18
79. A. Siew, H. Le, M. Thiovolet, P. Gellert, A. Schatzlein, and I. Uchegbu Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharm. 9 2011 14 28
80. J. Lai, Y. Lu, Z. Yin, F. Hu, and W. Wu Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles Int. J. Nanomedicine 5 2010 13 23
81. N. Fukata, K. Uchida, T. Kusuda, M. Koyabu, H. Miyoshi, T. Fukui, M. Matsushita, A. Nishio, Y. Tabata, and K. Okazaki The effective therapy of cyclosporine A with drug delivery system in experimental colitis J. Drug Target. 19 2011 458 467
82. H. Yu, D. Xia, Q. Zhu, C. Zhu, D. Chen, and Y. Gan Supersaturated polymeric micelles for oral cyclosporine A delivery Eur. J. Pharm. Biopharm. 85 2013 1325 1336
83. J. Azzi, L. Tang, R. Moore, R. Tong, N. El Haddad, T. Akiyoshi, B. Mfarrej, S. Yang, M. Jurewicz, T. Ichimura, N. Lindeman, J. Cheng, and R. Abdi Polylactide-cyclosporin A nanoparticles for targeted immunosuppression FASEB J. 24 2010 3927 3938
84. K. Jyothi, J. Beloor, A. Jo, M.N. Nguyen, T.G. Choi, J. Kim, S. Akter, S. Lee, C.H. Maeng, and H.H. Baik Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication Int. J. Nanomedicine 10 2015 903 921
85. P. Aksungur, M. Demirbilek, E.B. Denkbaş, J. Vandervoort, A. Ludwig, and N. Ünlü Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies J. Control. Release 151 2011 286 294
86. E. Basaran, E. Yenilmez, M.S. Berkman, G. Buÿükköroglu, and Y. Yazan Chitosan nanoparticles for ocular delivery of cyclosporine A J. Microencapsul. 31 2013 49 57
87. C. Di Tommaso, J. Bourges, F. Valamanesh, G. Trubitsyn, A. Torriglia, J. Jeanny, F. Behar-Cohen, R. Gurny, and M. Möller Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea penetration, ocular distribution and efficacy studies Eur. J. Pharm. Biopharm. 81 2012 257 264
88. X. Wang, and Q. Zhang pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs Eur. J. Pharm. Biopharm. 82 2012 219 229
89. R.H. Müller, S. Runge, V. Ravelli, W. Mehnert, A.F. Thünemann, and E.B. Souto Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals Int. J. Pharm. 317 2006 82 89
90. A. Beloqui, M. Solinís, A. Delgado, C. Evora, A. del Pozo-Rodríguez, and A. Rodríguez-Gascón Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: Influence of technological factors Eur. J. Pharm. Biopharm. 84 2013 309 314
91. S. Reimondez-Troitinõ, N. Csaba, M. Alonso, and M. de la Fuente Nanotherapies for the treatment of ocular diseases Eur. J. Pharm. Biopharm. 95 Part B 2015 279 293
92. Y. Wu, J. Yao, J. Zhou, and F.Z. Dahmani Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels Int. J. Nanomedicine 8 2013 3587 3601
93. S. Eperon, M. Rodriguez-Aller, K. Balaskas, R. Gurny, and Y. Guex-Crosier A new drug delivery system inhibits uveitis in an animal model after cataract surgery Int. J. Pharm. 443 2013 254 261
94. C. Gupta, and A. Chauhan Ophthalmic delivery of cyclosporine A by punctal plugs J. Control. Release 150 2011 70 76
95. M. Rodriguez-Aller, D. Guillarme, M. El Sanharawi, F. Behar-Cohen, J. Veuthey, and R. Gurny In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application J. Control. Release 170 2013 153 159
96. S.T. Kim, D. Jang, J.H. Kim, J.Y. Park, J.S. Lim, S.Y. Lee, K. Lee, S. Lim, and C. Kim Topical administration of cyclosporin A in a solid lipid nanoparticle formulation Pharmazie 64 2009 510 514
97. M. Frušić-Zlotkin, Y. Soroka, R. Tivony, L. Larush, L. Verkhovsky, F.M. Brégégère, R. Neuman, S. Magdassi, and Y. Milner Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model Exp. Dermatol. 21 2012 938 943
98. A.B. Watts, R.O. Williams III, and J.I. Peters Recent developments in drug delivery to prolong allograft survival in lung transplant patients Drug Dev. Ind. Pharm. 35 2009 259 271
99. X. Wu, W. Zhang, D. Hayes Jr., and H.M. Mansour Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery Int. J. Nanomedicine 8 2013 1269 1283
100. L. Baiza-Duran, J. Medrano-Palafox, E. Hernandez-Quintela, J. Lozano-Alcazar, and O.J.F. Alaniz-de la A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome Br. J. Ophthalmol. 94 2010 1312 1315
101. W. Shi, M. Chen, L. Xie, M. Liu, H. Gao, T. Wang, X. Wu, and J. Zhao A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: A clinical study Ophthalmology 120 2013 695 702